Presentation Operator Message
Operator (Operator)
Good day, and welcome to the positive interim analysis results of Phase II trial evaluating TG4001 plus avelumab conference call. At this time, I would
|
Marché Fermé -
Autres places de cotation
|
Varia. 5j. | Varia. 1 janv. | ||
| 0,7240 EUR | +0,14% |
|
-0,96% | -24,58% |
Publié le 02/11/2022 à 18:00
Presentation Operator Message
Operator (Operator)
Good day, and welcome to the positive interim analysis results of Phase II trial evaluating TG4001 plus avelumab conference call. At this time, I would
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national